Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA), currently trading at Rs. 1792.90, remains one of the best Pharma stocks India June 2026 as the sector navigates regulatory headwinds and emerging market opportunities. With a current trading price up 0.36% today and a 52-week range of Rs. 1548 to Rs. 1916.60, Sun Pharma faces stiff competition from peers like Dr. Reddy’s, Cipla, and Lupin in a rapidly evolving pharmaceutical landscape. This comprehensive peer comparison analysis examines valuation metrics, growth trajectories, and financial health to help investors identify the strongest Pharma stocks for long-term wealth creation in June 2026.
| Parameter | Details |
|---|---|
| Company Name | Sun Pharmaceutical Industries Ltd |
| NSE Symbol | SUNPHARMA |
| Current Price | Rs. 1792.90 |
| Today’s Change | +0.36% |
| Day Range | Rs. 1778.70 – Rs. 1794.90 |
| 52-Week Range | Rs. 1548.00 – Rs. 1916.60 |
| Volume | 489,052 shares |
| Sector | Pharmaceuticals |
The Pharma Sector Landscape in India
The Indian pharmaceutical sector stands at a critical juncture in June 2026. Global demand for generic medications continues to rise, while regulatory pressures from USFDA and European authorities intensify. Moreover, the shift toward specialty drugs and biosimilars creates new revenue streams for companies with robust R&D capabilities.
Indian Pharma companies collectively generate over Rs. 5 lakh crore in annual revenue. The sector contributes significantly to India’s export economy, with formulations and APIs finding markets across 200+ countries. However, pricing pressures in the US market and patent cliff challenges remain persistent headwinds.
Additionally, domestic market growth accelerates as health insurance penetration deepens. The government’s focus on affordable healthcare through schemes like Ayushman Bharat expands the addressable market. Therefore, identifying the best Pharma stocks India June 2026 requires analyzing both domestic and export performance metrics.
Sun Pharmaceutical Position Within the Sector
Sun Pharma maintains its position as India’s largest pharmaceutical company by market capitalization. The company operates across 100+ markets globally, with significant presence in the US, India, and emerging markets. Furthermore, its specialty portfolio in dermatology and ophthalmology differentiates it from pure-play generic competitors.
The company’s manufacturing footprint includes 42 facilities worldwide. Sun Pharma has successfully navigated USFDA compliance challenges that plagued it in previous years. Consequently, most of its critical facilities now operate without significant regulatory warnings.
Nevertheless, Sun Pharma faces intense competition from domestic peers. Dr. Reddy’s Laboratories, Cipla, Lupin, and Aurobindo Pharma compete aggressively in both domestic and international markets. Each company brings distinct strengths—be it biosimilars expertise, respiratory franchise, or cost leadership.
Valuation Comparison: PE, PB, EV/EBITDA
Valuation metrics provide crucial insights when comparing Pharma stocks. Traditional metrics like Price-to-Earnings and Price-to-Book help investors assess whether stocks trade at premium or discount. However, Enterprise Value to EBITDA offers a clearer picture by accounting for debt levels.
The following table compares key valuation parameters across leading Pharma stocks. These metrics help identify value opportunities among the best Pharma stocks India June 2026 based on fundamental analysis.
| Company | Current Price (Rs.) | PE Ratio | PB Ratio | EV/EBITDA |
|---|---|---|---|---|
| Sun Pharma | 1792.90 | 28.5 | 3.8 | 18.2 |
| Dr. Reddy’s Lab | 6145.30 | 24.3 | 4.2 | 16.8 |
| Cipla | 1456.80 | 26.7 | 3.5 | 17.4 |
| Lupin | 1823.50 | 32.1 | 2.9 | 19.6 |
| Aurobindo Pharma | 1267.40 | 21.8 | 2.6 | 14.3 |
| Torrent Pharma | 3156.70 |